Furthermore, recent evidence revealed that SGLT2 inhibitors, a new class of anti-diabetic drugs, were associated with improved overall survival of hepatocellular carcinoma (HCC) patients with pre-existing type 2 diabetes [48]. The gene discussed is SLC5A2; the disease is hepatocellular carcinoma.